prospect
consecut
enrol
infant
year
age
diagnosi
bronchiol
access
pediatr
emerg
depart
univers
hospit
padova
typic
rsv
season
itali
decemb
bronchiol
defin
first
episod
lower
respiratori
tract
infect
sign
respiratori
distress
crackl
chest
auscult
preced
coryz
ill
parent
approach
consent
infant
admit
emerg
depart
clinic
diagnosi
bronchiol
satisfi
none
follow
exclus
criteria
chronic
lung
diseas
ie
bronchopulmonari
dysplasia
cystic
fibrosi
interstiti
lung
diseas
neonat
respiratori
distress
chronic
condit
ie
congenit
heart
diseas
andor
immunocompromis
state
andor
histori
prematur
ie
birth
week
gestat
age
period
decemb
also
enrol
healthi
infant
year
age
histori
bronchiol
satisfi
exclus
criteria
list
enrol
children
help
local
pediatrician
studi
approv
ethic
committe
padova
univers
gener
hospit
protocol
parent
gave
written
inform
consent
children
particip
studi
time
recruit
parent
interview
aid
structur
questionnair
obtain
patient
clinic
histori
particular
provid
detail
pregnanc
deliveri
perinat
histori
auxolog
paramet
birth
vaccin
ongo
treatment
includ
vitamin
breastfeed
histori
wean
parent
smoke
habit
number
sibl
day
care
center
attend
famili
histori
allergi
parent
sibl
presenc
atop
eczema
detail
surgeri
diseas
previou
hospit
admiss
also
record
nasopharyng
aspir
collect
test
respiratori
virus
ie
rsv
human
rhinoviru
hrv
adenoviru
bocaviru
enteroviru
influenza
viru
b
parainfluenza
viru
type
metapneumoviru
coronaviru
parechoviru
use
polymeras
chain
reaction
analysi
urin
sampl
collect
infant
use
steril
bag
within
hour
arriv
emerg
depart
urin
sampl
store
metabolom
analysi
clinic
followup
perform
month
month
year
episod
bronchiol
monitor
histori
wheez
addit
inform
wheez
occur
episod
bronchiol
obtain
interview
famili
pediatrician
enrol
children
itali
children
year
old
routin
follow
famili
pediatrician
recurr
wheez
defin
episod
wheez
diagnos
pediatrician
followup
acut
episod
bronchiol
urin
sampl
analyz
mass
spectrometri
laboratori
depart
women
children
health
padova
univers
hospit
fondazion
istituto
di
ricerca
pediatrica
della
speranza
sampl
prepar
method
chromatograph
mass
spectrometri
condit
describ
previou
work
elsewher
articl
supplementari
materi
briefli
metabol
profil
urin
acquir
use
water
acquiti
ultraperform
liquid
chromatographi
system
coupl
water
qtof
synapt
mass
spectromet
water
milford
dilut
sampl
separ
column
acquiti
hss
dimens
mm
mm
pore
diamet
water
electrospray
sourc
oper
posit
neg
ioniz
mode
capillari
voltag
kv
kv
respect
data
collect
centroid
mode
mass
scan
rang
mz
resolut
oper
control
masslynx
water
qualiti
control
sampl
standard
solut
sampl
use
test
reproduc
accuraci
analysi
inject
regular
interv
throughout
sequenc
togeth
blank
sampl
water
formic
acid
sampl
randomli
inject
triplic
prevent
spuriou
classif
deriv
posit
sampl
sequenc
raw
data
convert
data
set
markerlynx
softwar
rtmass
variabl
filter
exclud
variabl
valu
miss
remain
miss
valu
data
imput
minimum
valu
relat
variabl
thu
probabilist
quotient
normal
use
correct
data
effect
reduct
perform
detector
analyt
session
differ
dilut
collect
sampl
data
log
transform
get
normal
distribut
center
around
mean
valu
multivari
data
analys
base
project
method
univari
data
analys
base
test
falsediscoveri
rate
receiv
oper
characterist
roc
curv
analysi
also
perform
specif
exploratori
data
analysi
perform
use
princip
compon
analysi
pca
project
latent
structur
discrimin
analysi
base
variabl
influenc
project
select
vipbas
plsda
use
identifi
differ
group
investig
multivari
project
method
linearli
combin
measur
variabl
obtain
compon
known
latent
variabl
provid
data
represent
effect
factor
includ
experiment
design
easili
investig
untarget
approach
measur
variabl
relev
aim
studi
variabl
select
use
improv
model
robust
procedur
call
stabil
select
implement
simplifi
model
interpret
procedur
stabil
select
base
mont
carlo
sampl
random
subsampl
use
pinpoint
subset
relev
variabl
character
group
investig
relev
variabl
select
submodel
gener
stabil
select
procedur
moreov
group
sampl
exclud
montecarlo
sampl
use
estim
predict
power
model
sevenfold
full
crossvalid
use
determin
number
compon
use
wherea
permut
analysi
class
respons
use
avoid
overfit
plsda
model
character
area
roc
curv
auc
fit
train
data
crossvalid
predict
sampl
exclud
stabil
select
aucpr
relev
variabl
select
light
multivari
data
analysi
merg
obtain
univari
data
analysi
thu
variabl
identifi
search
human
metabolom
databas
metlin
metabolit
databas
set
compound
identifi
investig
mean
pathway
overrepresent
analysi
supplementari
materi
total
infant
acut
bronchiol
recruit
median
age
day
rang
day
day
old
male
urin
sampl
nasopharyng
aspir
collect
patient
patient
hospit
etiolog
bronchiol
aspir
children
test
posit
rsv
test
posit
hrv
test
posit
virus
coronaviru
influenza
viru
test
neg
virus
two
year
patient
receiv
diagnosi
bronchiol
could
divid
differ
group
one
compris
children
recurr
wheez
experienc
episod
wheez
followup
hereaft
refer
recurr
wheez
group
consist
children
histori
wheez
episod
bronchiol
hereaft
refer
wheez
group
median
age
group
differ
significantli
p
mannwhitney
test
eleven
children
experienc
episod
wheez
followup
includ
comparison
wheez
nonwheez
group
tabl
show
characterist
metadata
subgroup
sever
bronchiol
assess
use
respiratori
syncyti
viru
network
scale
base
feed
intoler
medic
intervent
respiratori
difficulti
respiratori
frequenc
apnea
gener
condit
fever
signific
differ
emerg
metadata
recurr
wheez
wheez
group
tabl
total
healthi
infant
median
age
day
rang
day
histori
bronchiol
includ
final
analysi
seventeen
day
old
male
median
age
differ
acut
bronchiol
group
p
mannwhitney
test
none
develop
acut
bronchiol
recurr
wheez
followup
mass
spectrometri
urin
sampl
led
gener
data
set
neg
data
set
includ
rtmass
variabl
po
data
set
compris
rtmass
variabl
obtain
process
raw
data
group
acquir
neg
posit
ioniz
mode
respect
exploratori
data
analysi
base
pca
identifi
outlier
observ
level
basi
hotel
test
dmodx
test
signific
level
data
set
combin
investig
use
multivari
univari
data
analys
first
step
data
analysi
metabol
profil
urin
specimen
control
group
compar
urin
specimen
children
bronchiol
obtain
reliabl
plsda
model
capabl
distinguish
group
show
compon
auc
p
auc
calcul
full
crossvalid
p
median
aucpr
calcul
mean
stabil
select
percentil
score
scatterplot
model
shown
figur
model
underw
posttransform
accord
method
stocchero
pari
differ
metabol
profil
obtain
urin
sampl
children
recurr
wheez
children
wheez
investig
use
vipbas
plsda
stabil
select
obtain
reliabl
plsda
model
capabl
distinguish
group
show
compon
auc
p
auc
calcul
full
crossvalid
p
median
aucpr
calcul
stabil
select
percentil
score
scatterplot
model
posttransform
shown
figur
variabl
earmark
stabil
select
procedur
merg
highlight
test
falsediscoveri
rate
p
q
roc
analysi
p
auc
obtain
set
relev
variabl
identifi
supplementari
tabl
twenti
variabl
show
specif
show
sensit
search
avail
onlin
metabolit
databas
found
plausibl
identif
subset
variabl
compris
put
marker
list
tabl
set
put
marker
investig
use
pathway
overrepresent
analysi
see
human
metabol
pathway
show
differ
arrang
children
subsequ
develop
recurr
wheez
differ
metabol
arrang
emerg
citric
acid
cycl
p
lysin
biosynthesi
p
lysin
degrad
p
cystein
methionin
metabol
p
moreov
obtain
reliabl
plsda
model
capabl
distinguish
wheez
group
healthi
children
compon
auc
p
auc
calcul
full
crossvalid
p
median
aucpr
calcul
stabil
select
percentil
correl
acut
bronchiol
preschool
wheez
demonstr
abundantli
medic
literatur
mani
studi
suggest
children
episod
rsvrelat
bronchiol
infanc
like
recurr
wheez
especi
bronchiol
sever
follow
time
children
spirometr
valu
consist
reduc
airway
patenc
school
age
similar
associ
found
hrvrelat
bronchiol
mechan
connect
bronchiol
longterm
respiratori
problem
fulli
understood
author
suggest
causal
role
bronchiol
asthma
sinc
prevent
rsv
infect
monoclon
antibodi
seem
reduc
risk
recurr
wheez
other
hypothes
preexist
alter
lung
function
predispos
bronchiol
subsequ
recurr
wheez
whatev
mechan
involv
remain
unclear
children
histori
acut
bronchiol
infanc
later
develop
recurr
wheez
asthma
given
asthma
common
chronic
respiratori
diseas
childhood
identifi
children
histori
bronchiol
would
benefit
earli
treatment
close
followup
program
import
goal
pediatr
metabolom
appli
asthmat
children
effort
improv
understand
pathogenesi
asthma
better
character
differ
phenotyp
led
identif
specif
metabol
pattern
individu
although
virus
known
capabl
reprogram
metabol
pathway
publish
studi
appli
metabolom
bronchiol
recent
demonstr
analysi
metabolom
profil
urin
nasopharyng
aspir
differenti
healthi
children
viral
respiratori
tract
infect
discrimin
differ
degre
diseas
sever
metabolom
nasopharyng
aspir
obtain
infant
bronchiol
also
reveal
potenti
distinguish
infant
infect
hrv
oppos
rsv
possibl
correl
metabolom
pictur
develop
acut
bronchiol
subsequ
onset
recurr
wheez
never
investig
demonstr
process
acut
bronchiol
sever
disrupt
metabol
profil
comparison
profil
healthi
children
figur
also
identifi
differ
metabol
profil
infant
acut
bronchiol
could
distinguish
would
would
subsequ
develop
recurr
wheez
pathway
analysi
reveal
major
role
citric
acid
cycl
discrimin
p
isocitr
citric
acid
oxoglutar
acid
central
metabolit
citric
acid
cycl
appear
critic
separ
group
citric
acid
cycl
key
metabol
pathway
occur
matrix
mitochondrion
gener
energi
produc
cellular
respir
cycl
may
influenc
pathophysiolog
respiratori
tract
diseas
clear
alter
may
sign
disrupt
cellular
energi
metabol
reflect
condit
stress
increas
anaerob
glycolysi
could
explain
inflammatori
condit
asthma
character
metabol
alter
chang
citric
acid
cycl
induc
rsv
infect
alreadi
demonstr
previou
studi
studi
add
perturb
discrimin
children
develop
recurr
wheez
also
found
evid
alter
metabol
lysin
cystein
methionin
point
possibl
influenc
amino
acid
pathway
alreadi
suggest
elsewher
anoth
metabolit
found
disrupt
isobutyrylglycin
nbutyrylglycin
minor
metabolit
fatti
acid
reduct
shortchain
fatti
acid
level
report
children
asthma
studi
conduct
canada
infant
risk
asthma
exhibit
lower
level
fecal
acet
associ
transient
gut
microbi
dysbiosi
shortchain
fatti
acid
deriv
bacteri
ferment
therefor
profoundli
influenc
gut
microbiota
recent
casecontrol
studi
also
identifi
specif
fecal
microbiota
profil
associ
higher
likelihood
develop
bronchiol
emerg
differ
fatti
acid
metabolit
children
without
recurr
wheez
suggest
differ
composit
gut
microbiota
might
associ
onset
condit
recent
studi
possibl
mechan
connect
gut
microbiota
respiratori
tract
diseas
point
gutmedi
lung
immun
author
postul
exist
gutlung
axi
find
alter
nacetylneuramin
acid
profil
suggest
involv
bacteria
pathogen
process
bronchiol
sinc
higher
level
nacetylneuramin
acid
intestin
mucosa
influenc
outgrowth
bacteria
serv
sourc
nutrient
find
may
contribut
better
understand
mechan
behind
recurr
wheez
acut
bronchiol
import
bear
mind
children
without
recurr
wheez
distinguish
basi
overal
metabol
profil
rather
differ
specif
metabolit
clinic
standpoint
data
may
provid
basi
earli
identif
children
like
develop
recurr
wheezingasthma
could
benefit
target
therapi
prevent
measur
strength
present
studi
includ
criteria
select
patient
base
strict
definit
bronchiol
infant
year
old
thu
avoid
risk
overlap
bronchiol
wheez
clear
identif
wheez
episod
base
pediatrician
diagnosi
rather
parent
report
use
urin
specimen
metabolom
analysi
collect
fundament
consider
pediatr
popul
statist
standpoint
robust
procedur
intern
model
valid
use
support
find
potenti
limit
studi
mainli
concern
small
sampl
size
brief
followup
period
aspect
may
influenc
result
studi
lack
associ
bronchiol
sever
respiratori
outcom
report
larger
studi
noteworthi
children
includ
rsv
bronchiol
studi
includ
children
nonrsv
bronchiol
particularli
hrv
bronchiol
need
evalu
whether
metabolom
result
depend
viru
involv
acut
infect
also
import
emphas
interpret
specif
metabolit
might
relat
onset
recurr
wheez
still
specul
studi
need
better
character
biochem
structur
metabolit
emerg
role
onset
recurr
wheez
moreov
present
studi
includ
independ
valid
cohort
preliminari
data
repres
first
step
improv
understand
biolog
complex
bronchiol
wheez
diseas
addit
investig
possibl
corrobor
preliminari
find
would
interest
see
whether
basal
urinari
metabolom
profil
episod
acut
bronchiol
reveal
associ
subsequ
onset
recurr
wheez
thu
establish
whether
respons
lie
virusinduc
bronchiol
preexist
predispos
condit
conclus
use
metabolom
evalu
urin
sampl
infant
acut
bronchiol
caus
rsv
enabl
us
differenti
children
subsequ
develop
recurr
wheez
although
find
demand
extern
valid
may
contribut
better
understand
pathogen
mechan
behind
incept
wheez
disord
acut
bronchiol
children
develop
recurr
wheez
character
disrupt
citric
acid
cycl
amino
acid
metabol
investig
need
clarifi
possibl
role
chang
interest
result
emerg
studi
remain
characterist
overal
metabolom
profil
associ
onset
recurr
wheez
acut
bronchiol
find
pave
way
develop
noninvas
tool
earli
identif
infant
high
risk
wheez
could
benefit
target
therapi
prevent
measur
